From the MS Trust website:
06 July 2010 - Market Watch
Genmab announces interim results from a Phase II study of ofatumumab in RRMS
Genmab A/S announced today positive interim results from an ofatumumab Phase II safety and pharmacokinetics study in patients with relapsing-remitting multiple sclerosis (RRMS).
For full article click here.